ATE370932T1 - Ccr-3-rezeptorantagonisten vii - Google Patents

Ccr-3-rezeptorantagonisten vii

Info

Publication number
ATE370932T1
ATE370932T1 AT02803781T AT02803781T ATE370932T1 AT E370932 T1 ATE370932 T1 AT E370932T1 AT 02803781 T AT02803781 T AT 02803781T AT 02803781 T AT02803781 T AT 02803781T AT E370932 T1 ATE370932 T1 AT E370932T1
Authority
AT
Austria
Prior art keywords
ccr
vii
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT02803781T
Other languages
English (en)
Inventor
Bois Daisy Du
Beihan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE370932T1 publication Critical patent/ATE370932T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT02803781T 2001-11-30 2002-11-20 Ccr-3-rezeptorantagonisten vii ATE370932T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33481901P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE370932T1 true ATE370932T1 (de) 2007-09-15

Family

ID=23308965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02803781T ATE370932T1 (de) 2001-11-30 2002-11-20 Ccr-3-rezeptorantagonisten vii

Country Status (16)

Country Link
US (1) US7019007B2 (de)
EP (1) EP1453804B1 (de)
JP (1) JP2005518364A (de)
KR (1) KR100579352B1 (de)
CN (1) CN1296356C (de)
AR (1) AR037586A1 (de)
AT (1) ATE370932T1 (de)
AU (1) AU2002356694A1 (de)
BR (1) BR0214611A (de)
CA (1) CA2468402A1 (de)
DE (1) DE60222015T2 (de)
ES (1) ES2291539T3 (de)
MX (1) MXPA04004980A (de)
PL (1) PL373275A1 (de)
RU (1) RU2004120065A (de)
WO (1) WO2003045917A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0111878A (pt) * 2000-06-30 2005-05-24 Bristol Myers Squibb Co N-ureido-(heterociclo-alquil)-piperidinas como moduladores da atividade de receptores de quimiocinas
CA2502178A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
EP1610753A4 (de) * 2003-02-20 2007-07-04 Encysive Pharmaceuticals Inc Phenylendiamin-urotensin-ii-rezeptorantagonisten und ccr-9-antagonisten
CA2531167C (en) 2003-06-30 2012-05-22 Sumitomo Chemical Company, Limited Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
US7541468B2 (en) * 2004-06-10 2009-06-02 Bristol-Myers Squibb Company Process of preparing N-ureidoalkyl-piperidines
EP2621923B1 (de) * 2010-09-29 2017-03-29 Intervet International B.V. N-heteroarylverbindungen mit cyclischer überbrückungseinheit zur behandlung von parasitären erkrankungen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953005A (en) * 1961-02-24 1964-03-18 Soc Ind Fab Antibiotiques Sifa Substituted n-phenylethyl-n-phenyl-piperazines
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6455528B1 (en) * 1997-10-14 2002-09-24 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BR9917038A (pt) * 1998-12-18 2002-04-02 Du Pont Pharm Co Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2346933A1 (en) 1998-12-18 2000-06-22 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69926919D1 (de) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1205473A4 (de) * 1999-07-28 2004-06-16 Daiichi Radioisotope Lab Vesamicol-piperazin-derivate und medikamente die diese enthalten
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
KR100579352B1 (ko) 2006-05-12
ES2291539T3 (es) 2008-03-01
AU2002356694A1 (en) 2003-06-10
JP2005518364A (ja) 2005-06-23
CA2468402A1 (en) 2003-06-05
BR0214611A (pt) 2004-09-14
CN1599721A (zh) 2005-03-23
US20030153578A1 (en) 2003-08-14
MXPA04004980A (es) 2004-08-11
AR037586A1 (es) 2004-11-17
EP1453804A2 (de) 2004-09-08
RU2004120065A (ru) 2005-05-27
PL373275A1 (en) 2005-08-22
EP1453804B1 (de) 2007-08-22
US7019007B2 (en) 2006-03-28
WO2003045917A3 (en) 2003-10-09
DE60222015D1 (de) 2007-10-04
CN1296356C (zh) 2007-01-24
DE60222015T2 (de) 2008-06-05
KR20040062663A (ko) 2004-07-07
WO2003045917A2 (en) 2003-06-05
WO2003045917B1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
ATE368659T1 (de) Thrombinrezeptorantagonisten
ATE346043T1 (de) Il-8-rezeptorantagonisten
NO20025754L (no) IL-8 Reseptor-antagonister
DE60112051D1 (de) Il-8 rezeptor antagonisten
ATE374183T1 (de) Nk1-antagonisten
ATE353215T1 (de) Il-8 rezeptor-antagonisten
DE60130000D1 (de) Zwitterionische tachykinin-rezeptor-antagonisten
NO20024554D0 (no) IL-8 reseptorantagonister
DK1372688T3 (da) Somatostatin-antagonister
DK1180028T3 (da) IL-8-receptorantagonister
ATE370932T1 (de) Ccr-3-rezeptorantagonisten vii
NO20024367L (no) IL-8 reseptorantagonister
NO20015774L (no) IL-8 reseptorantagonister
PL370367A1 (en) Ccr-3 receptor antagonists v
NO20033223D0 (no) Histamin-reseptor antagonister
DE60209885D1 (de) Crf receptor antagonisten
NO20024366D0 (no) IL-8 reseptorantagonister
DE60134427D1 (de) Exzitatorische aminosäure-rezeptor-antagonisten
SE0003996D0 (sv) Receptorantagonister
DK1131291T3 (da) 4-aroyl-piperidin-CCR-3-receptorantagonister III

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties